Abstract
Introduction
The diagnosis of psychiatric diseases is an inexact science and a slow process
for physicians. No laboratory tests are available to determine the exact
disease-or treatment. New diagnostic technologies could offer earlier, more
specifi c diagnosis of a psychiatric disease and even direct potential drug
therapy. In this report, we discuss the treatment challenges that confront
physicians and patients and review current and emerging diagnostic tests that
are expected to change the way in which psychiatric diseases are diagnosed.
This report also features three Expert Commentaries, two offering input from
the diagnostic technology industry, and one highlighting Decision Resources'
primary research with physicians who discuss their views of biomarkerbased
diagnostic tests for psychiatry.
Get the Answers You Need to Shape Your Strategy
- The diagnosis of mental illness is far from an exact science, with no
laboratory tests to confi rm a disorder or offer treatment strategies. What
technologies are emerging that will expedite diagnosis and treatment of
psychiatric disorders? How will these technologies affect R&D within the
pharmaceutical industry?
- EEG, molecular, genetic, and imaging diagnostics are all poised for use in
the fi eld of psychiatry. How will the technologies that exist to aid
diagnosis expand into the fi eld of mental health? What companies already have
clinical trials under way and what diagnostic tools are they using? How will
these studies target patient response to some of today' s most popular
psychiatric drugs? What challenges do manufacturers face when developing these
diagnostics?
- Expert Commentaries: two company executives and one market analyst discuss
the impact of novel diagnostics in the psychiatric arena. What are thought
leaders saying about the potential for biomarkers in mental health diagnosis
and treatment? How will a new EEG tool help psychiatrists target drug therapy
in their patients? How can gene-expression profi les lead to differential
diagnoses or offer insight into disease-specifi c subtyping?
Scope
- Diffi culties diagnosing mental illness: addressing similar
symptomatology; multiple mental illnesses in one patient; challenges in
determining optimal treatment; current medical practice for psychiatric
indications.
- Current and emerging diagnostic technologies for psychiatric
indications: EEG (Aspect Medical Systems, CNS Response, Memory
Pharmaceuticals/Roche); molecular diagnostics (Clinical Data, CombiMatrix,
Curidium Medica, Roche/Affymetrix, Vanda Pharmaceuticals); diagnostic imaging
(Alseres).
- Psychiatric disorders: attention-defi cit/hyperactivity disorder;
autism spectrum disorder; bipolar disorder; major depression; schizophrenia;
psychotic disorders.
- Business considerations: review of partnerships and licensing
activities; benefi ts of drug/theranostic codevelopment; challenges and
opportunities.
| 
View Cart
